Thyroid Cancer Post-Op Risk Stratification

How to use: Enter the key features from the surgical pathology report. The calculator applies the ATA 2015 Management Guidelines for Differentiated Thyroid Cancer to assign an initial post-operative risk tier (Low · Intermediate · High), generate a radioactive iodine recommendation with activity range, and outline surveillance targets.

Applies to: Differentiated Thyroid Cancer (DTC) — Papillary Thyroid Carcinoma (PTC) and Follicular Thyroid Carcinoma (FTC) only. Does not apply to medullary, anaplastic, or poorly differentiated carcinoma.

1

Histologic Type

Select the primary diagnosis from the pathology report

Papillary Thyroid Carcinoma (PTC) — classical or follicular variantIncludes encapsulated follicular variant (EFV-PTC)

PTC — aggressive variantTall cell, hobnail, columnar cell, solid/trabecular, diffuse sclerosing, or widely invasive

Follicular Thyroid Carcinoma (FTC) — minimally invasiveEncapsulated with limited capsular invasion; no or minimal vascular invasion (≤3 vessels)

FTC — widely invasiveExtensive vascular invasion (>4 vessels) or widely invasive

Hürthle Cell Carcinoma (Oncocytic FTC)Minimally or widely invasive

2

Tumor Extent & Completeness of Resection

Based on surgical and pathology findings

Extra-thyroidal Extension (ETE)

None — tumor confined to thyroid

Microscopic ETE (pETE) Minimal invasion of perithyroidal soft tissue (T3b) — detected only on histology

Macroscopic / Gross ETE Invasion of strap muscles (T4a) or trachea/larynx/esophagus/RLN (T4b)

Completeness of Resection (R status)

R0 — Complete macroscopic resection, all gross disease removed

R1 — Microscopic residual disease at margins

R2 — Gross residual disease / incomplete resection

Vascular Invasion (for FTC/Hürthle; also applies to PTC)

None

Minor vascular invasion 1–3 vessels invaded

Extensive vascular invasion ≥4 vessels invaded

Tumor Size

Microcarcinoma ≤1 cm

1–2 cm

2–4 cm

>4 cm

Multifocality

Unifocal

Multifocal Multiple tumor foci

3

Lymph Node Status (N Stage)

From pathology report and operative findings

N0 — No lymph node metastases (clinical or pathologic)

N1 — ≤5 micrometastatic nodes All involved nodes <0.2 cm; minimal extranodal extension

N1 — >5 involved nodes, all <3 cm Including central and/or lateral compartment nodes

N1 — Any node ≥3 cm, or gross extranodal extension

4

Distant Metastases (M Stage)

M0 — No distant metastases

M1 — Distant metastases present Lung, bone, brain, liver, or other distant sites

ATA 2015 Risk Tier Reference

Summary of criteria defining each initial risk category

✅ Low Risk

Intrathyroidal PTC; no vascular invasion; N0 or ≤5 micrometastatic nodes (<0.2 cm)
Intrathyroidal, encapsulated follicular variant PTC (EFV-PTC)
Intrathyroidal, well-differentiated FTC with no or minimal capsular invasion and no vascular invasion
Intrathyroidal papillary microcarcinoma (unifocal or multifocal, including BRAF V600E if known)
No aggressive histology; no ETE; R0 resection; no distant metastases
Estimated recurrence risk: 1–10%

⚠️ Intermediate Risk

Microscopic ETE (perithyroidal soft tissue invasion) on histology
Aggressive histological variant (tall cell, hobnail, columnar cell, diffuse sclerosing, solid)
PTC with minor vascular invasion (1–3 vessels)
Clinically apparent N1 or >5 pathologically involved nodes, all <3 cm
Multifocal papillary microcarcinoma with ETE
Hürthle cell carcinoma (all grades)
Estimated recurrence risk: 11–30%

🔴 High Risk

Macroscopic / gross ETE (T4a or T4b)
Incomplete macroscopic resection (R1/R2)
Distant metastases (M1)
Any pathologic N1 node ≥3 cm, or gross extranodal extension
FTC with extensive vascular invasion (≥4 vessels) or widely invasive FTC
Estimated recurrence risk: >30%

RAI Activity Guide (ATA 2015)

Risk Tier	RAI Indication	Typical Activity	Goal
Low Risk	Not routinely recommended. May be considered if remnant ablation would aid staging or ease follow-up.	30–50 mCi (1.1–1.85 GBq) if given	Remnant ablation only
Intermediate Risk	Generally recommended; individualize based on clinical features and extent of disease.	50–150 mCi (1.85–5.55 GBq)	Remnant ablation ± adjuvant treatment
High Risk	Strongly recommended in all cases.	100–200 mCi (3.7–7.4 GBq)	Adjuvant treatment ± treatment of known disease
Distant Metastases (M1)	RAI if lesions are RAI-avid; dosimetry-guided dosing preferred.	100–200+ mCi; dosimetry-guided	Treat known distant disease

Dynamic Risk Stratification — Response to Therapy

After initial therapy (surgery ± RAI), risk is reassigned dynamically at 6–12 months based on imaging and biochemistry. This response-to-therapy category guides ongoing surveillance intensity.

Response Category	Definition	Estimated Residual Risk
Excellent	No clinical, biochemical, or structural evidence of disease. Suppressed Tg <0.2 ng/mL (or stimulated Tg <1 ng/mL), negative TgAb, negative imaging.	1–4% disease-specific mortality
Biochemical Incomplete	Elevated Tg or rising TgAb without structural disease on imaging.	~30% develop structural disease; <1% disease-specific mortality
Structural Incomplete	Persistent or newly identified locoregional or distant structural disease regardless of Tg.	50–85% disease-specific mortality (depending on site)
Indeterminate	Nonspecific biochemical or structural findings — low-level Tg, nonspecific imaging abnormalities, stable TgAb.	~15–20% will have structural disease on follow-up

TSH Suppression Targets

Risk / Response	TSH Target	Duration
High risk (initial)	<0.1 mU/L	Indefinitely while structurally disease-free; reassess annually
Intermediate risk (initial)	0.1–0.5 mU/L	5–10 years; can liberalize with excellent response
Low risk / Excellent response	0.5–2.0 mU/L (low-normal)	May allow normal TSH after 5 years if Tg undetectable
Structural incomplete response	<0.1 mU/L	Continue suppression while active disease present